28 days is the FDA requirement for producers of multi-use vials to prove their bacteriostatic maintains efficacy
Progress monitoring at weeks 4, 8, and 12 with protocol adjustment
Breastfeeding : There is insufficient data regarding use during lactation, and the potential risks to the infant are unknown
Anti-inflammatory protein upregulation: Simultaneously increases expression of anti-inflammatory proteins like IL-10, TGF- (in controlled amounts), and various inflammation resolution mediators (lipoxins, resolvins)
Additionally, it serves as a coenzyme in several metabolic pathways responsible for energy production, aiding the body to metabolize fats and proteins
For patients suffering from debilitating fatigue and post-exertional malaise (PEM), this cellular-level energy support is critical